216 related articles for article (PubMed ID: 31053403)
1. Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.
Mohankumar K; Li X; Sridharan S; Karki K; Safe S
Gynecol Oncol; 2019 Jul; 154(1):218-227. PubMed ID: 31053403
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.
Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S
Endocr Relat Cancer; 2015 Oct; 22(5):831-40. PubMed ID: 26229035
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.
Hedrick E; Li X; Cheng Y; Lacey A; Mohankumar K; Zarei M; Safe S
Breast Cancer Res Treat; 2019 Aug; 177(1):29-40. PubMed ID: 31119568
[TBL] [Abstract][Full Text] [Related]
4. Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS).
Lacey A; Hedrick E; Li X; Patel K; Doddapaneni R; Singh M; Safe S
Oncotarget; 2016 May; 7(21):31257-69. PubMed ID: 27144436
[TBL] [Abstract][Full Text] [Related]
5. Bis-Indole-Derived Nuclear Receptor 4A1 (NR4A1, Nur77) Ligands as Inhibitors of Endometriosis.
Mohankumar K; Li X; Sung N; Cho YJ; Han SJ; Safe S
Endocrinology; 2020 Apr; 161(4):. PubMed ID: 32099996
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma.
Hedrick E; Lee SO; Kim G; Abdelrahim M; Jin UH; Safe S; Abudayyeh A
PLoS One; 2015; 10(6):e0128308. PubMed ID: 26035713
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NR4A1 Promotes ROS Accumulation and IL24-Dependent Growth Arrest in Rhabdomyosarcoma.
Hedrick E; Mohankumar K; Lacey A; Safe S
Mol Cancer Res; 2019 Nov; 17(11):2221-2232. PubMed ID: 31462501
[TBL] [Abstract][Full Text] [Related]
8. NR4A1 Antagonists Inhibit β1-Integrin-Dependent Breast Cancer Cell Migration.
Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S
Mol Cell Biol; 2016 May; 36(9):1383-94. PubMed ID: 26929200
[TBL] [Abstract][Full Text] [Related]
9. The nuclear orphan receptor NR4A1 regulates β1-integrin expression in pancreatic and colon cancer cells and can be targeted by NR4A1 antagonists.
Hedrick E; Lee SO; Safe S
Mol Carcinog; 2017 Sep; 56(9):2066-2075. PubMed ID: 28418095
[TBL] [Abstract][Full Text] [Related]
10. The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells.
Lee SO; Jin UH; Kang JH; Kim SB; Guthrie AS; Sreevalsan S; Lee JS; Safe S
Mol Cancer Res; 2014 Apr; 12(4):527-538. PubMed ID: 24515801
[TBL] [Abstract][Full Text] [Related]
11. Flavonoids Quercetin and Kaempferol Are NR4A1 Antagonists and Suppress Endometriosis in Female Mice.
Zhang L; Mohankumar K; Martin G; Mariyam F; Park Y; Han SJ; Safe S
Endocrinology; 2023 Aug; 164(10):. PubMed ID: 37652054
[TBL] [Abstract][Full Text] [Related]
12. The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells.
Shrestha R; Mohankumar K; Jin UH; Martin G; Safe S
Mol Cancer Ther; 2021 Mar; 20(3):612-622. PubMed ID: 33277444
[TBL] [Abstract][Full Text] [Related]
13. Nuclear receptor 4A1 (NR4A1) antagonists target paraspeckle component 1 (PSPC1) in cancer cells.
Mohankumar K; Shrestha R; Safe S
Mol Carcinog; 2022 Jan; 61(1):73-84. PubMed ID: 34699643
[TBL] [Abstract][Full Text] [Related]
14. New Drug Candidate Targeting the 4A1 Orphan Nuclear Receptor for Medullary Thyroid Cancer Therapy.
Zhang L; Liu W; Wang Q; Li Q; Wang H; Wang J; Teng T; Chen M; Ji A; Li Y
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498706
[TBL] [Abstract][Full Text] [Related]
15. Targeting NR4A1 (TR3) in cancer cells and tumors.
Lee SO; Li X; Khan S; Safe S
Expert Opin Ther Targets; 2011 Feb; 15(2):195-206. PubMed ID: 21204731
[TBL] [Abstract][Full Text] [Related]
16. The orphan nuclear receptor NR4A1 promotes FcεRI-stimulated mast cell activation and anaphylaxis by counteracting the inhibitory LKB1/AMPK axis.
Jin F; Li X; Deng Y; Timilshina M; Huang B; Kim DY; Chang JH; Ichinose H; Baek SH; Murakami M; Lee YJ; Chang HW
Allergy; 2019 Jun; 74(6):1145-1156. PubMed ID: 30565708
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
18. Bis-Indole Derivatives as Dual Nuclear Receptor 4A1 (NR4A1) and NR4A2 Ligands.
Upadhyay S; Hailemariam AE; Mariyam F; Hafiz Z; Martin G; Kothari J; Farkas E; Sivaram G; Bell L; Tjalkens R; Safe S
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540704
[TBL] [Abstract][Full Text] [Related]
19. A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
Karki K; Wright GA; Mohankumar K; Jin UH; Zhang XH; Safe S
Cancer Res; 2020 Mar; 80(5):1011-1023. PubMed ID: 31911554
[TBL] [Abstract][Full Text] [Related]
20. Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells.
Lee SO; Li X; Hedrick E; Jin UH; Tjalkens RB; Backos DS; Li L; Zhang Y; Wu Q; Safe S
Mol Endocrinol; 2014 Oct; 28(10):1729-39. PubMed ID: 25099012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
